2024 - NCI-CONNECTions
-
A new trial investigates zotiraciclib as a treatment for people with recurrent gliomas containing an IDH1 or IDH2 mutation to control tumor growth and improve quality of life.
-
In a new systematic review, researchers identify the specific challenges that make it difficult for this patient population to enroll in clinical trials and seek specialized treatment.
-
Paul has lived with a recurring ependymoma of the brain and spine for most of his life. In that time, he has found connection in the NCI-CONNECT community, comfort in spirituality, and trust in his care team.